Pharmaceuticals & Therapeutics

GOA Therapeutics is combining venture backing and institutional placements with retail crowdfunding as part of a $300 million strategy to fund its alcohol poisoning antidote candidate.

As highly palatable veterinary medications flood the market, accidental cross-species overdoses are exposing critical gaps in pet-safe packaging.

French biotech EVerZom successfully completes preclinical studies for its exosome-based EVerGel, targeting a 2027 clinical debut for Crohn's disease fistulas.

As Compass Pathways targets a 2027 launch for its psilocybin therapy, a new HR chief highlights the shift from clinical pioneer to commercial enterprise.

A multi-agency GCP inspection forces AB Science to delay its lead ALS and AML trials to 2027, testing investor patience and a new turnaround strategy.

Azurity's newly approved liquid lamotrigine isn't just a convenience—it's a critical safety measure for pediatric epilepsy and bipolar patients facing high risks.

Fueled by surging Iqirvo royalties and a new Medicare diagnostic code, GENFIT is quietly restructuring its pipeline to dominate intensive care hepatology.

Lupin’s tentative FDA approval for a liquid alternative to Eliquis highlights a strategic pivot toward value-added formulations and onshore manufacturing.

A new partnership highlights how enzymatic synthesis could solve the scaling and stereochemistry crises facing next-generation RNA therapeutics.

As BioAge prepares for major investor conferences, the biotech firm is nearing a critical Phase 2 readout that could redefine cardiometabolic and obesity care.

As global myopia rates surge, the FDA faces a high-stakes showdown over Sydnexis's SYD-101. The outcome will redefine pediatric eye care and supply chains.

With a unique off-the-shelf stem cell therapy, BOOST Pharma is poised to reshape pediatric care for osteogenesis imperfecta as it seeks Phase III partners.

Applying advanced pharmacokinetic simulations, Luye Pharma is challenging a $2.9 billion market by proposing flexible dosing strategies for its antipsychotic ERZOFRI.

Crystalys Therapeutics names Tim Walbert as Chairman, signaling a bold commercial push for its de-risked gout therapy dotinurad as it enters Phase 3 trials.

Ophirex's Phase 2 trial missed its primary goals, but subgroup data and a rare FDA pathway could salvage a game-changing oral snakebite treatment.

KVK-Tech announced a flawless FDA inspection this week. But behind the press release lies a complex story of federal monitors and generic drug economics.

Kedrion Biopharma secures Orphan Drug Designation for QIVIGY in Stiff Person Syndrome, leveraging regulatory incentives to build a commercial moat.

As Recludix readies for the Oppenheimer showcase, its Sanofi-partnered STAT6 inhibitor signals a structural shift from biologics to oral small molecules.

By leveraging deuterated chemistry, Aviva Bio aims to bypass the oncologic risks that have stalled FDA approval for female testosterone therapies for decades.

With standard-of-care avacopan facing global regulatory withdrawal, InflaRx is stepping into the void. A strategic look at the upcoming Capital Markets Day and the mechanics of clinical resilience.